

## Holding(s) in Company

December 4, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)

<b>1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached<sup>i</sup>:</b>		Shire plc (LEI: 54930005LQRLI2UXRQ59)		
<b>1b. Please indicate if the issuer is a non-UK issuer</b> (please mark with an “X” if appropriate)				
Non-UK issuer				
<b>2. Reason for the notification</b> (please mark the appropriate box or boxes with an “X”)				
An acquisition or disposal of voting rights				X
An acquisition or disposal of financial instruments				
An event changing the breakdown of voting rights				
Other (please specify) <sup>iii</sup> :				
<b>3. Details of person subject to the notification obligation<sup>iv</sup></b>				
Name		Susan Kilsby (Chairman of Shire plc and proxy holder)		
City and country of registered office (if applicable)				
<b>4. Full name of shareholder(s)</b> (if different from 3.) <sup>v</sup>				
Name		Third parties holding ADRs on behalf of the person identified in box 3 and shareholders appointing (i) the Chairman of Shire plc as proxy and (ii) a designate of Shire plc as proxy.		
City and country of registered office (if applicable)				
<b>5. Date on which the threshold was crossed or reached<sup>vi</sup>:</b>		December 3, 2018		
<b>6. Date on which issuer notified (DD/MM/YYYY):</b>		December 4, 2018		
<b>7. Total positions of person(s) subject to the notification obligation</b>				
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuer <sup>vii</sup>
Resulting situation on the date on which threshold was crossed or reached	7.65%		7.65%	915,888,124

Position of previous notification (if applicable)				
---	--	--	--	--

**8. Notified details of the resulting situation on the date on which the threshold was crossed or reached<sup>viii</sup>**

**A: Voting rights attached to shares**

Class/type of shares ISIN code (if possible)	Number of voting rights <sup>x</sup>		% of voting rights	
	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
JE00B2QKY057 (Shire plc Ordinary Shares of 5 pence each)		70,089,867		7.65%
<b>SUBTOTAL 8. A</b>	70,089,867		7.65%	

**B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))**

Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>xi</sup>	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
		<b>SUBTOTAL 8. B 1</b>		

**B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))**

Type of financial instrument	Expiration date <sup>x</sup>	Exercise/ Conversion Period <sup>xi</sup>	Physical or cash settlement <sup>xii</sup>	Number of voting rights	% of voting rights
			<b>SUBTOTAL 8.B.2</b>		

**9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)**

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer <sup>xiii</sup>	X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity <sup>xiv</sup> (please add additional rows as necessary)	

Name <sup>xv</sup>	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

**10. In case of proxy voting, please identify:**

Name of the proxy holder	Susan Kilsby (Chairman of Shire plc)
The number and % of voting rights held	70,063,380 / 7.65%
The date until which the voting rights will be held	The conclusion of Shire plc’s General Meeting to be held on December 5, 2018, or any adjournment thereof.

**11. Additional information<sup>xvi</sup>**

The number of indirect voting rights includes 70,063,380 voting rights, being the maximum number of discretionary proxy votes held by the Chairman of Shire plc pursuant to proxies received in respect of the resolution to be considered by shareholders at the Shire plc General Meeting to be held on December 5, 2018. These voting rights will expire immediately upon the conclusion of the General Meeting, or any adjournment thereof. The appointment of a proxy shall not preclude a shareholder of Shire plc from attending and voting in person at the General Meeting.

<b>Place of completion</b>	Dublin, Ireland
<b>Date of completion</b>	December 4, 2018

**For further information please contact:**

**Investor Relations**

Christoph Brackmann	<a href="mailto:christoph.brackmann@shire.com">christoph.brackmann@shire.com</a>	+41 41 288 41 29
Sun Kim	<a href="mailto:sun.kim@shire.com">sun.kim@shire.com</a>	+1 617 588 8175
Scott Burrows	<a href="mailto:scott.burrows@shire.com">scott.burrows@shire.com</a>	+41 41 288 4195

## **Media**

Katie Joyce	<a href="mailto:kjoyce@shire.com">kjoyce@shire.com</a>	+1 781 482 2779
-------------	--	-----------------

## **NOTES TO EDITORS**

### **About Shire**

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what's next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.

Championing patients is our call to action - it brings the opportunity - and responsibility - to change people's lives.

[www.shire.com](http://www.shire.com)